Key Takeaway
The FDA is poised to render a decision on Moderna's mRNA-based flu shot, which could be the first of its kind to market. The decision is expected to reverberate throughout the biotech industry.
Published August 1, 2026 · Category: News
Overview
The FDA is poised to render a decision on Moderna's mRNA-based flu shot, which could be the first of its kind to market. The decision is expected to reverberate throughout the biotech industry.
Details
(Image credit: Maddie Meyer)
Source
Originally published at www.npr.org.
Related Articles
Frequently Asked Questions
What is "FDA weighs a new kind of flu shot based on technology RFK Jr. has questioned" about?+
The FDA is poised to render a decision on Moderna's mRNA-based flu shot, which could be the first of its kind to market. The decision is expected to reverberate throughout the biotech industry.
Who reported this story?+
This story was reported by NPR News.